Humasis said on Tuesday that it has filed a creditor objection to the merger of Celltrion and Celltrion Healthcare. Celltrion's shareholders voted on Oct. 23 to acquire Celltrion Healthcare in a merger of equals.

In January, Celltrion filed a 60 billion won ($46.6 million) lawsuit against Humasis, alleging damages from the non-delivery of Covid-19 diagnostic kits. In February, Humasis countersued for 120 billion won ($93.2 million), citing non-payment of supply contracts and damages.

Responding to Celltrion's lawsuit, Humasis stated it was willing to accept Celltrion's request to suspend production and extend delivery dates but rejected the demand for excessive unit price cuts and subsidies.

Humasis argued that when it declined the unit price reduction and subsidy, Celltrion claimed to terminate the contract due to a delay in delivery, even though it had never sought delay compensation.

"The merger cannot be registered if the relevant procedures are violated," said a Humasis official. "If Celltrion does not fulfill the legal procedures such as repayment and collateral, Humasis will notify the competent registry office of the existence of bonds to block the Celltrion merger."

In response, a Celltrion official said, "We do not expect this to have a significant impact on the merger." "We will actively respond to the creditor objection after conducting an internal review to ensure that there are no problems with the merger."